Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211766 · ClinicalTrials.gov registry record · NA
Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT04211766: Completed NA study, sponsored by Fred Hutchinson Cancer Center.
NCT04211766 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04211766, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This trial studies how fiber and fish oil supplements affect the metabolism and activities of colon cells in healthy individuals. Diet is an important risk factor for colorectal cancer, and several dietary components important in colorectal cancer prevention are modified by gut microbial metabolism. Giving fiber and fish oil supplements may inhibit the growth of gut cells and ultimately reduce risk of colorectal cancer.
Primary Outcome
This grant is an R21 with the intent to provide preliminary data to propose a trial with a larger sample size and adequate statistical power.
Interventions
- DIETARY_SUPPLEMENT Dietary Fiber
- DIETARY_SUPPLEMENT Fish Oil
- OTHER Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2022-08-16 |
| Phase | NA |
What the finished NCT04211766 record still lists
NCT04211766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Dietary Fiber is the first listed.
NCT04211766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04211766 about?
NCT04211766 is a clinical study titled "Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer". This trial studies how fiber and fish oil supplements affect the metabolism and activities of colon cells in healthy individuals. Diet is an important risk factor for colorectal cancer, and several dietary components important in colorectal cancer prevention are modified by gut microbial metabolism....
What is the current status of trial NCT04211766?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2021-01-05. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT04211766?
The interventions under investigation include: Dietary Fiber (DIETARY_SUPPLEMENT), Fish Oil (DIETARY_SUPPLEMENT), Comparator (OTHER).
Who is sponsoring clinical trial NCT04211766?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04211766's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI